Search

Your search keyword '"Amorim, Sandy"' showing total 9 results
Start Over Author "Amorim, Sandy" Publication Year Range Last 3 years
9 results on '"Amorim, Sandy"'

1. Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort

Author

Ghesquières, Hervé, Cherblanc, Fanny, Belot, Aurélien, Micon, Sophie, Bouabdallah, Krimo K., Esnault, Cyril, Fornecker, Luc-Matthieu, Thokagevistk, Katia, Bonjour, Maxime, Bijou, Fontanet, Haioun, Corinne, Morineau, Nadine, Ysebaert, Loïc, Damaj, Gandhi, Tessoulin, Benoit, Guidez, Stéphanie, Morschhauser, Franck, Thiéblemont, Catherine, Chauchet, Adrien, Gressin, Rémy, Jardin, Fabrice, Fruchart, Christophe, Labouré, Gaëlle, Fouillet, Ludovic, Lionne-Huyghe, Pauline, Bonnet, Antoine, Lebras, Laure, Amorim, Sandy, Leyronnas, Cécile, Olivier, Gaelle, Guieze, Romain, Houot, Roch, Launay, Vincent, Drénou, Bernard, Fitoussi, Olivier, Detourmignies, Laurence, Abraham, Julie, Soussain, Carole, Lachenal, Florence, Pica, Gian Matteo, Fogarty, Patrick, Cony-Makhoul, Pascale, Bernier, Adeline, Le Guyader-Peyrou, Sandra, Monnereau, Alain, Boissard, Frédéric, Rossi, Cédric, and Camus, Vincent

Published
2024
Full Text
View/download PDF

2. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group

Author

Aubrais, Raphaelle, Bouabdallah, Krimo, Chartier, Loic, Herbaux, Charles, Banos, Anne, Brice, Pauline, Sibon, David, Schiano, Jean Marc, Cluzeau, Thomas, Laribi, Kamel, Le Calloch, Ronan, Bellal, Mathieu, Delapierre, Baptiste, Daguindau, Nicolas, Amorim, Sandy, Agbetiafa, Kossi, Chauchet, Adrien, Besson, Caroline, Durot, Eric, Bonnet, Christophe, Fouillet, Ludovic, Bijou, Fontanet, Tournilhac, Olivier, Gaulard, Philippe, Parrens, Marie-Cécile, and Damaj, Gandhi

Published
2023
Full Text
View/download PDF

3. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

Author

Driessen, Julia, Kersten, Marie José, Visser, Lydia, van den Berg, Anke, Tonino, Sanne H., Zijlstra, Josée M., Lugtenburg, Pieternella J., Morschhauser, Franck, Hutchings, Martin, Amorim, Sandy, Gastinne, Thomas, Nijland, Marcel, Zwezerijnen, Gerben J. C., Boellaard, Ronald, de Vet, Henrica C. W., Arens, Anne I. J., Valkema, Roelf, Liu, Roberto D. K., Drees, Esther E. E., de Jong, Daphne, Plattel, Wouter J., and Diepstra, Arjan

Published
2022
Full Text
View/download PDF

4. Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort

Author

Ghesquieres, Herve, primary, Cherblanc, Fanny, additional, Belot, Aurelien, additional, Micon, Sophie, additional, Bouabdallah, Krimo, additional, Esnault, Cyril, additional, Fornecker, Luc-Matthieu, additional, Thokagevistk, Katia, additional, Bonjour, Maxime, additional, Bijou, Fontanet, additional, Haioun, Corinne, additional, Morineau, Nadine, additional, Ysebaert, Loïc, additional, Damaj, Gandhi, additional, Tessoulin, Benoit, additional, Guidez, Stéphanie, additional, Morschhauser, Franck, additional, Thieblemont, Catherine, additional, Chauchet, Adrien, additional, Gressin, Remy, additional, Jardin, Fabrice, additional, Fruchart, Christophe, additional, Labouré, Gaelle, additional, Fouillet, Ludovic, additional, Lionne-Huyghe, Pauline, additional, Bonnet, Antoine, additional, Lebras, Laure, additional, Amorim, Sandy, additional, Leyronnas, Cecile, additional, Olivier, Gaelle, additional, Guieze, Romain, additional, Houot, Roch, additional, Launay, Vincent, additional, Drénou, Bernard, additional, Fitoussi, Olivier, additional, Detourmignies, Laurence, additional, Abraham, Julie, additional, Soussain, Carole, additional, Lachenal, Florence, additional, Pica, Gian Matteo, additional, Fogarty, Patrick, additional, Cony-Makhoul, Pascale, additional, Bernier, Adeline, additional, Le Guyader-Peyrou, Sandra, additional, Monnereau, Alain, additional, Boissard, Frédéric, additional, Rossi, Cédric, additional, and Camus, Vincent, additional

Published
2023
Full Text
View/download PDF

5. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA

Author

Aubrais, Raphaelle, primary, Bouabdallah, Krimo, additional, chartier, loic, additional, Herbaux, Charles, additional, Banos, Anne, additional, Brice, Pauline, additional, Sibon, David, additional, Schiano, Jean Marc, additional, Cluzeau, Thomas, additional, Laribi, Kamel, additional, LE CALLOCH, Ronan, additional, bellal, Mathieu, additional, Delapierre, Baptiste, additional, daguindau, nicolas, additional, Amorim, Sandy, additional, Agbetiafa, Kossi, additional, Chauchet, Adrien, additional, besson, caroline, additional, Durot, Eric, additional, Bonnet, Christophe, additional, Fouillet, Ludovic, additional, Bijou, Fontanet, additional, Tournilhac, Olivier, additional, Gaulard, Philippe, additional, Parrens, Marie-Cécile, additional, and Damaj, Gandhi, additional

Published
2022
Full Text
View/download PDF

7. Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study

Author

Bouabdallah, Krimo, primary, Aubrais, Raphaëlle, additional, Chartier, Loïc, additional, Herbaux, Charles, additional, Banos, Anne, additional, Brice, Pauline, additional, Ochmann, Marlene, additional, Sibon, David, additional, Schiano De Colella, Jean Marc, additional, Cluzeau, Thomas, additional, Laribi, Kamel, additional, Le Calloch, Ronan, additional, Bellal, Mathieu, additional, Daguindau, Nicolas, additional, Amorim, Sandy, additional, Agbetiafa, Kossi, additional, Chauchet, Adrien, additional, Hammami, Marwa, additional, Durot, Eric, additional, Bonnet, Christophe, additional, Robles, Margot, additional, Fouillet, Ludovic, additional, Bijou, Fontanet, additional, Tournilhac, Olivier, additional, Gaulard, Philippe, additional, Parrens, Marie, additional, Milpied, Noel-Jean, additional, and Damaj, Gandhi Laurent, additional

Published
2021
Full Text
View/download PDF

8. Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study

Author

Lazarovici, Julien, primary, Amorim, Sandy, additional, Bouabdallah, Krimo, additional, Guidez, Stéphanie, additional, Molina, Lysiane, additional, Morschhauser, Franck, additional, Gac, Anne-Claire, additional, Gastinne, Thomas, additional, Laribi, Kamel, additional, Launay, Vincent, additional, Slama, Bohrane, additional, Belmecheri, Nawel, additional, Casasnovas, René-Olivier, additional, Corby, Anne, additional, Durot, Eric, additional, Feugier, Pierre, additional, Nicolas-Virelizier, Emmanuelle, additional, Sibon, David, additional, Berriolo-Riedinger, Alina, additional, Edeline, Veronique, additional, Vander Borght, Thierry, additional, Damotte, Diane, additional, Traverse-Glehen, Alexandra, additional, Andre, Marc, additional, and Ribrag, Vincent, additional

Published
2021
Full Text
View/download PDF

9. Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.

Author

Carras S, Torroja A, Emadali A, Montaut E, Daguindau N, Tempescul A, Moreau A, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Barbieux S, Corm S, Banos A, Fouillet L, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouabdallah K, Amorim S, Garidi R, Voillat L, Joly B, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Burroni B, Callanan M, Le Gouill S, and Gressin R

Subjects
Humans, Aged, Female, Male, Aged, 80 and over, Prognosis, Rituximab therapeutic use, Rituximab administration & dosage, Treatment Outcome, Bendamustine Hydrochloride administration & dosage, Bendamustine Hydrochloride therapeutic use, Dexamethasone therapeutic use, Dexamethasone administration & dosage, Doxorubicin therapeutic use, Doxorubicin administration & dosage, Lymphoma, Mantle-Cell drug therapy, Lymphoma, Mantle-Cell genetics, Lymphoma, Mantle-Cell mortality, Lymphoma, Mantle-Cell pathology, Tumor Suppressor Protein p53 genetics, Mutation, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Hypoalbuminemia etiology
Abstract

Between 2011 and 2012, a phase II trial evaluated the use of the RiBVD (rituximab, bendamustine, velcade and dexamethasone) combination as first-line treatment for mantle cell lymphoma (MCL) patients over the age of 65. We have now re-examined the classic prognostic factors, adding an assessment of TP53 mutation status. Patients (N=74; median age 73 years) were treated with the RiBVD combination. Median progression-free survival (mPFS) was 79 months and median overall survival (mOS) was 111 months. TP53 mutation status was available for 54/74 (73%) patients. TP53 mutations (TP53mt) were found in 12 patients (22.2%). In multivariate analysis, among the prognostic factors (PF) evaluated, only TP53mt and an albumin level (Alb) 3.6 g/dL were independently associated with a shorter mPFS. A hazard ratio (HR) of 3.16 (1.3-9.9, P=0.014) was obtained for TP53mt versus TP53 wild-type (wt), and 3.6 (1.39-9.5, P=0.009) for Alb <3.6 g/dL versus Alb ≥3.6 g/dL. In terms of mOS, multivariate analysis identified three PF: TP53mt (HR: 5.9 [1.77-19.5, P=0.004]), Alb <3.6 g/dL (HR: 5.2 [1.46- 18.5, P=0.011]), and ECOG=2 (HR: 3.7 [1.31-10.6, P=0.014]). Finally, a score combining TP53 status and Alb distinguished three populations based on the presence of 0, 1, or 2 PF. For these populations, mPFS was 7.8 years, 28 months, and 2.5 months, respectively. Our prolonged follow-up confirmed the efficacy of the RiBVD regimen, comparing it favorably to other regimens. TP53mt and hypoalbuminemia emerge as strong PF that can be easily integrated into prognostic scores for older adult patients with MCL.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results